Symptom Response to Repeat Dose Intravenous Psychedelic Therapy in Adults with Major Depressive and Bipolar Disorder

Symptom Response to Repeat Dose Intravenous Psychedelic Therapy in Adults with Major Depressive and Bipolar Disorder: Results from The Canadian Rapid Treatment Center of Excellence

Multiple studies have demonstrated antidepressant effects of intravenous (IV) Psychedelic Therapy for unipolar and bipolar treatment-resistant depression (TRD). However, these studies have not delineated which specific symptoms of depression are more commonly improved by IV Psychedelic Therapy. Understanding which specific symptoms are more likely to improve with IV Psychedelic Therapy may be helpful for setting patient expectations and gauging treatment response.

Two hundred and twenty-six adults with treatment resistant major depressive disorder (MDD) and bipolar depression (BD) received repeated doses of IV Psychedelic Therapy at a community-based clinic. Depressive symptoms (sleep, mood, appetite/weight, concentration, self-criticism, suicidal ideation, general interest, energy, psychomotor restlessness/agitation) were measured by the Quick Inventory for Depression-Self-Report 16-Item (QIDS-SR16) at five timepoints: (1) baseline, (2) post-infusion 1, (3) post-infusion 2, (4) post-infusion 3, and (5) post-acute assessment. The data were analyzed using mixed models to determine the effect of repeated IV Psychedelic Therapy treatment on each of the nine symptoms. Symptom improvements were categorized as clinically important if patients exhibited a 30% decrease in symptoms from baseline to the post-acute assessment.

Download Full Publication

Related Articles

  •

    Safety and tolerability of IV Psychedelic Therapy in adults with major depressive or bipolar disorder

    Nelson B. Rodrigues

    Expert Opinion on Drug Safety (Taylor & Francis) , 2020

    Rigorous clinical trials suggest Psychedelic Therapy is safe and well-tolerated in patients with treat-ment-resistant depression (TRD). There is a paucity of data on the safety and tolerability of Psychedelic Therapy in community-based clinics treating patients with TRD.

    Read More

  • Oral Psychedelic Therapy for Depression

    Joshua D. Rosenblat, MD

    The Journal of Clinical Psychiatry (J Clin Psychiatry) , 2019

    Intravenous (IV) Psychedelic Therapy has rapid and robust antidepressant effects; however, poor accessibility of the IV route often limits its use Numerous alternative routes of administration are being investigated. Oral Psychedelic Therapy is particularly appealing for its ease of use with the potential for high accessibility.

    Read More

  • Registered Psychedelic Therapy trials

    Bahareh Peyrovian

    Journal of Psychiatric Research , 2020

    As interest has grown in the potential psychiatric applications of Psychedelic Therapy, the number of registered clinical trials has grown substantially. Herein, we summarize and analyze clinical trials registered with ClinicalTrials.gov

    Read More